SP13#4
ESi006-A
General
Cell Line |
|
| hPSCreg Name | ESi006-A |
| Alternative name(s) |
SP13#4
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Last update | 4th September 2022 |
| User feedback | |
Provider |
|
| Generator | Spanish Stem Cell Bank (ES) |
| Distributors | |
| Derivation country | Spain |
External Databases |
|
| BioSamples | SAMEA3303225 |
| Cellosaurus | CVCL_V203 |
| EBiSC | ESi006-A |
| ECACC | 66540068 |
| CLO | CLO_0101547 |
| Wikidata | Q54955440 |
General Information |
|
| Publications | |
| Projects | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 65-69 |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Disease associated phenotypes |
|
External Databases (Donor) |
|
| BioSamples | SAMEA3303187 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Provide contact information of the holder of the original Donor Information Sheet: | baran@idibell.cat |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | No |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent pertain to a specific research project? | Yes |
| Details on restriction to research project | Generation of stem cells, pluripotent cells and derivation of dopaminergic neurons in patients with sporadic and familial Parkinson's disease. |
| Does consent permit unforeseen future research, without further consent? | No |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | No |
| Does consent expressly permit collection of genetic information? | Yes |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
| How may genetic information associated with the cell line be accessed? | No information |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | Yes |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | Yes |
| Does consent permit access to medical records of the donor? | No |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Ethics Committee Center of Regenerative Medicine in Barcelona |
| Approval number | |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Ethics Committee Center of Regenerative Medicine in Barcelona |
| Approval number | |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
hIPSC Derivation
General |
|
| Source cell type |
keratinocyteAn epidermal cell which synthesizes keratin and undergoes a characteristic change as it moves upward from the basal layers of the epidermis to the cornified (horny) layer of the skin. Successive stages of differentiation of the keratinocytes forming the epidermal layers are basal cell, spinous or prickle cell, and the granular cell.
|
| Age of donor (at collection) | 65-69 |
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Virus (Retrovirus) |
| Genes | |
| Is the used vector excisable? |
Unknown |
| Absence of reprogramming vector(s)? |
Unknown |
| Reprogramming vectors silenced? |
Yes |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Gelatin | |||||||||||||||
| Feeder cells |
Human foreskin fibroblasts Cellfinder Ont Id: CELDA_000001419 |
|||||||||||||||
| Passage method | Mechanically | |||||||||||||||
| CO2 Concentration | 5 % | |||||||||||||||
| Medium |
Other medium:
Base medium: Knockout DMEM
Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| Alkaline Phosphatase |
Yes |
|
||||
| NANOG |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
||||
| SSEA-3 |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| TRA 1-81 |
Yes |
|
||||
| SOX2 |
Yes |
|
Differentiation Potency
In vivo teratoma
In vitro spontaneous differentiation
| Marker | Expressed |
| SMA |
Yes |
In vivo teratoma
In vitro spontaneous differentiation
| Marker | Expressed |
| Tuj1 |
Yes |
| GFAP |
Yes |
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Certificate of Analysis |
|
| Is there a certificate of analysis available? |
Yes
Passage:
19
|
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
|
Login to share your feedback, experiences or results with the research community.